Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis.

ABSTRACT: As many as 25% of patients diagnosed with ulcerative colitis are hospitalized with an episode of acute severe ulcerative colitis (ASUC).¹ The standard of care for patients hospitalized with ASUC relies on rapid induction with intravenous (IV) corticosteroids. Up to 30% of patients do not respond to corticosteroids alone.² Rescue therapy with infliximab or cyclosporine has been shown to reduce rates of colectomy to 20% by 90 days.^3,4 This still represents a significant rate of treatment failure, which leads to an unplanned and irreversible surgery. In recent years, increasing numbers of patients admitted with ASUC have already failed infliximab therapy, highlighting the need for additional treatment options for these patients. Tofacitinib is a rapidly acting

SUBMITTER: Berinstein JA 

PROVIDER: S-EPMC7194692 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature